Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $7.9552W HIGH $28.25
Volume
8.15 M
Value Traded
36.48 M
Short % Float
34.85%
+2.51%Week
+9.56%1 Month
+0.38%3 Month
-8.35%6 Month
-80.44%5 Year
-42.73%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
1.83 B
EPS (TTM)
-2.85
P/E Ratio
-
Ent. Value
1.20 B
Total Shares
140.13 M
Float Shares
133.94 M
Insiders
4.42%
Institutions
99.57%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
NTLA Catalyst Timeline
Dated clinical, regulatory and corporate events for Intellia Therapeutics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Intellia Therapeutics, Inc.
720Total events
26Upcoming
131Tier-1 (high impact)
2016 to 2028Coverage
Upcoming catalysts 2
Event history 50
▲FDA Filing Acceptedlonvo-zFiledRegulatory Filing
FDA accepts BLA for lonvo-z in HAE
Hereditary Angioedema (HAE)source ↗
▲AdCom Cancelledlonvo-zFiledAdvisory Committee
FDA not currently planning advisory committee for lonvo-z BLA
Hereditary Angioedema (HAE)source ↗
▲Primary Endpoint Metlonvo-zFiledClinical Data
HAELO met primary and all key secondary endpoints
hereditary angioedemasource ↗
▲Enrollment Completelonvo-zFiledTrial
HAELO fully enrolled with 80 patients in nine months
hereditary angioedemasource ↗
▲FDA Filing Acceptedlonvoguran ziclumeranFiledRegulatory Filing
FDA accepts BLA for lonvo-z in HAE
Hereditary Angioedema (HAE)source ↗
▲Priority Reviewlonvoguran ziclumeranFiledRegulatory Filing
FDA grants Priority Review for lonvo-z BLA
Hereditary Angioedema (HAE)source ↗
▲Debt Royalty FinancingCorporate
Intellia enters into $400 million non-dilutive senior secured term loan facility with OrbiMed
▲Oral Presentationlonvo-zFiledPresentation
Late-breaking oral presentation of additional positive Phase 3 results for lonvo-z at EAACI 2026
hereditary angioedemasource ↗
▲Publicationlonvo-zFiledPresentation
HAELO manuscript simultaneously published in the New England Journal of Medicine
hereditary angioedemasource ↗
▲Primary Endpoint Metlonvo-zFiledClinical Data
HAELO met primary endpoint with 87% reduction in mean monthly attacks
hereditary angioedemasource ↗
▲Secondary Endpoint Datalonvo-zFiledClinical Data
Key secondary endpoints met: 89% reduction in attacks requiring on-demand treatment, 91% reduction in moderate/severe attacks, and significant AE-QoL improvement
hereditary angioedemasource ↗
◆Poster PresentationPresentation
Poster presentation on barriers to normalization among HAE patients in Europe at EAACI 2026
hereditary angioedemasource ↗
◆Oral Presentationlonvo-zFiledPresentation
Additional clinical data from HAELO to be presented at EAACI Congress
Hereditary Angioedema (HAE)source ↗
◆Oral Presentationlonvoguran ziclumeranFiledPresentation
Additional HAELO data to be presented at EAACI Congress 2026
hereditary angioedemasource ↗
◆Oral PresentationPresentation
Intellia management to participate in fireside chat at Jefferies Global Healthcare Conference
◆Topline Readoutlonvo-zFiledClinical Data
Topline data from HAELO Phase 3 study of lonvo-z expected by mid-2026
hereditary angioedema (HAE)source ↗
▲Oral Presentationlonvo-zFiledPresentation
Additional HAELO data presented at EAACI 2026
hereditary angioedemasource ↗
▲Publicationlonvo-zFiledPresentation
HAELO results published in New England Journal of Medicine
hereditary angioedemasource ↗
◆Oral PresentationPresentation
Intellia management to participate in fireside chat at RBC Capital Markets Global Healthcare Conference
◆Oral PresentationPresentation
Intellia management to participate in fireside chat at Bank of America Securities Health Care Conference
▼Equity OfferingCorporate
Pricing of underwritten public offering of 16,744,187 shares at $10.75 per share
◆Equity OfferingCorporate
Intellia announces proposed public offering of $150 million common stock
◆Topline Readoutlonvoguran ziclumeranFiledClinical Data
Topline data from global Phase 3 HAELO trial of lonvoguran ziclumeran in hereditary angioedema
hereditary angioedemasource ↗
◆Oral Presentationlonvoguran ziclumeranFiledPresentation
Webcast to discuss topline data from Phase 3 HAELO trial
hereditary angioedemasource ↗
▲Primary Endpoint Metlonvo-zFiledClinical Data
Phase 3 HAELO trial met primary and all key secondary endpoints
hereditary angioedemasource ↗
●BLA Submissionlonvo-zFiledRegulatory Filing
Initiated rolling BLA submission to FDA
hereditary angioedemasource ↗
▲Primary Endpoint Metlonvoguran ziclumeranFiledClinical Data
Primary endpoint met in Phase 3 HAELO trial
hereditary angioedemasource ↗
▲Secondary Endpoint Datalonvoguran ziclumeranFiledClinical Data
All key secondary endpoints met with statistical significance
hereditary angioedemasource ↗
●Rolling Submission Initiatedlonvoguran ziclumeranFiledRegulatory Filing
Rolling BLA submission initiated to FDA
hereditary angioedemasource ↗
●BLA Submissionlonvoguran ziclumeranFiledRegulatory Filing
Initiated rolling submission of BLA to FDA for lonvo-z
hereditary angioedemasource ↗
●Rolling Submission Initiatedlonvo-zFiledRegulatory Filing
Rolling BLA submission for lonvo-z initiated with FDA in April 2026
hereditary angioedemasource ↗
▲Topline Readoutlonvo-zFiledClinical Data
Positive topline results from Phase 3 HAELO trial of lonvo-z in HAE
hereditary angioedemasource ↗
▲Primary Endpoint Metlonvo-zFiledClinical Data
HAELO met primary endpoint: 87% attack reduction vs placebo
Hereditary Angioedema (HAE)source ↗
◆Topline Readoutlonvoguran ziclumeranFiledClinical Data
Topline readout from Phase 3 HAELO trial expected by mid-2026
hereditary angioedemasource ↗
●Timing GuidanceNTLA-2002Presentation
Potential BLA submission for NTLA-2002 for HAE
hereditary angioedema (HAE)source ↗
●Oral Presentationnex-zPresentation
Phase 1 data presented at Peripheral Nerve Society Annual Meeting
ATTR amyloidosissource ↗
◆Oral PresentationPresentation
Intellia management to participate in fireside chat at Leerink Partners Global Healthcare Conference 2026
◆Oral PresentationPresentation
Intellia management to participate in fireside chat at TD Cowen 46th Annual Health Care Conference
◆ATM ProgramCorporate
Amendment to Open Market Sale Agreement increasing maximum offering amount to $1,035,316,650
▲Clinical Hold Liftednexiguran ziclumeranIND
FDA lifts clinical hold on MAGNITUDE Phase 3 trial of nex-z in ATTR-CM
transthyretin amyloidosis with cardiomyopathy (ATTR-CM)source ↗
▲Poster PresentationPresentation
Poster presentation at AAAAI 2026: Quantitative Systems Biology Modeling Estimates Extent of Excessive Kallikrein Generation in HAE Patients
Hereditary Angioedemasource ↗
●Poster PresentationPresentation
Poster presentation at AAAAI 2026: Chronic Medications Pose Challenges for People Living with HAE
Hereditary Angioedemasource ↗
◆Quarterly UpdateCorporate
Q4 and full-year 2025 financial results and business updates conference call
Past FDA Catalysts and PDUFA Decisions
How NTLA actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-06-30 | Lonvoguran Ziclumeran (lonvo-z, also known as NTLA-2002) | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C51 / 100
Pipeline Score
$263M
Pipeline Value
Richly Valued
Valuation Signal
2
Drugs Scored
0.1x
rNPV / MCap
Top 17%
Micro Cap(rank 113 of 660)
Percentile Rank
Intellia Therapeutics, Inc. carries a moderate pipeline score (51/100), with $674M risk-adjusted pipeline value, led by NTLA-2002 in Hereditary Angioedema (Phase 3).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NTLA-2002 Monoclonal antibodyNCT05120830 | Hereditary Angioedema | Phase 3 | ACTIVE NOT_RECRUITING | 117 | May 31, 2027 |
Clinical Trial Results
Readouts, endpoints and source filings for every NTLA program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| lonvoguran ziclumeran PriorityRMATOrphan | hereditary angioedema | Phase 3 | 2026-06-13 | 87% reduction in mean monthly attacks; 62% of patients in the lonvo-z arm were entirely attack free; 11% of patients in the placebo arm were entirely attack freeRead More | Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary AngioedemaRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Dube Michael POfficer (VP, Chief Accounting Officer) | Sell | -1,864 65,022 held | $12.43 | 10/02/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in NTLA
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 0.7 % | 76.59 M | 4.53 M | 30,079.51% ( 4.51 M) |
NTLA Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How NTLA ranks across every disease it competes in
Competitive Position is a premium feature
See how NTLA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialNTLA News
NTLAIntellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Intellia Therapeutics announced the awarding of inducement grants to eight new employees as part of its 2024 Inducement Plan. The grants, totaling 44,450 shares in restricted stock units, are designed to encourage long-term employment. This initiative aligns with Nasdaq Listing Rule 5635(c)(4) and reflects Intellia's commitment to attracting skilled professionals.
Read more →NTLAIntellia Therapeutics Announces FDA Acceptance of Biologics License Application with Priority Review for Lonvoguran Ziclumeran (Lonvo-z) for Hereditary Angioedema (HAE)
Intellia Therapeutics announced that the FDA has accepted its Biologics License Application for lonvoguran ziclumeran (lonvo-z) and granted it Priority Review, with a PDUFA date set for March 10, 2027. If approved, lonvo-z would be the first in vivo CRISPR-based therapy and a one-time treatment for hereditary angioedema (HAE). The application is supported by positive Phase 3 trial data showing significant reductions in monthly attacks.
Read more →NTLAIntellia Therapeutics Secures Non-Dilutive Debt Facility with OrbiMed for up to $400 Million
Intellia Therapeutics has secured a $400 million non-dilutive senior secured term loan facility with OrbiMed. This funding will enhance Intellia's financial flexibility as it aims for the U.S. approval and launch of lonvoguran ziclumeran (lonvo-z) for hereditary angioedema. The loan includes an initial $75 million and additional funds contingent on milestone achievements.
Read more →NTLAIntellia Therapeutics to Present at Morgan Stanley 24th Annual Global Healthcare Conference
Intellia Therapeutics, a biopharmaceutical leader in CRISPR gene editing, will present at the Morgan Stanley 24th Annual Global Healthcare Conference on September 14, 2026. The presentation will be accessible via a live webcast, with a replay available for 90 days. Intellia's mission is to develop potentially curative treatments for severe diseases.
Read more →NTLAIntellia Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates
Intellia Therapeutics reported strong Q2 2026 results, highlighted by positive Phase 3 data for lonvo-z in hereditary angioedema (HAE). The company anticipates FDA acceptance of its biologics license application (BLA) for lonvo-z in the latter half of 2026, with a U.S. launch expected in early 2027. Additionally, enrollment in the nex-z Phase 3 trials has resumed, and new genomic insights have been gained.
Read more →NTLAIntellia Therapeutics to Hold Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Business Updates
Intellia Therapeutics will host a conference call on August 6, 2026, to discuss its second quarter financial results and business updates. The call will be accessible via webcast and teleconference for both U.S. and international participants. A replay will be available for 90 days on the company's website.
Read more →NTLA▲ +23.2%on this news
Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema
Intellia Therapeutics presented promising Phase 3 results for lonvo-z in treating hereditary angioedema at the EAACI Annual Congress 2026. The trial demonstrated an 87% reduction in monthly attacks and a significant portion of patients remained attack-free. The findings were published in the New England Journal of Medicine, supporting the drug's potential for regulatory approval in 2027.
Read more →NTLAIntellia Therapeutics to Report Additional Phase 3 HAELO Data for Lonvoguran Ziclumeran (lonvo-z) in Late-Breaking Oral Presentation at EAACI 2026
Intellia Therapeutics will present additional Phase 3 data for lonvo-z at the EAACI Annual Congress 2026. The study focuses on hereditary angioedema (HAE) and will include a late-breaking oral presentation and a poster on patient burdens. Lonvo-z aims to be a groundbreaking CRISPR-based treatment for HAE.
Read more →NTLAIntellia Therapeutics Announces First Quarter 2026 Financial Results and Business Updates
Intellia Therapeutics reported positive Phase 3 results for lonvo-z, a CRISPR-based treatment for hereditary angioedema (HAE), showing an 87% reduction in attacks. The company initiated a rolling BLA submission to the FDA, aiming for a U.S. launch in early 2027. Additionally, patient screening for nex-z in ATTR amyloidosis trials has resumed, and Intellia's financial resources are projected to support operations through at least 2028.
Read more →NTLAIntellia Therapeutics to Participate in Upcoming Investor Conferences
Intellia Therapeutics, Inc. has announced its participation in several upcoming investor conferences, including the Bank of America Securities Health Care Conference, RBC Capital Markets Global Healthcare Conference, and Jefferies Global Healthcare Conference. The fireside chats will provide opportunities for management to discuss the company's advancements in CRISPR gene editing and other technologies. Webcasts of these presentations will be available live, with replays accessible for 90 days afterward. Intellia's focus remains on developing potentially curative treatments for severe diseases.
Read more →NTLAIntellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 1, 2026
Intellia Therapeutics announced the awarding of inducement grants to 43 new employees under its 2024 Inducement Plan. The grants, totaling 208,850 shares in restricted stock units (RSUs), will vest over three years, contingent on continued employment. This move is part of Intellia's strategy to attract talent and is compliant with Nasdaq regulations.
Read more →NTLA▼ -5.7%on this newsshared move
Intellia Therapeutics Announces Pricing of Public Offering of Common Stock
Intellia Therapeutics has announced the pricing of a public offering of 16,744,187 shares at $10.75 each, aiming to raise around $180 million. The offering is underwritten by Jefferies, Goldman Sachs, and Citigroup, with a 30-day option for underwriters to purchase additional shares. The completion of the offering is subject to market conditions.
Read more →NTLAIntellia Announces Proposed Public Offering of Common Stock
Intellia Therapeutics has announced a proposed public offering of $150 million in common stock. The offering includes a 30-day option for underwriters to purchase an additional 15% of the shares. The offering is subject to market conditions, and the company aims to leverage its CRISPR gene editing technology to advance its clinical programs.
Read more →NTLAIntellia Therapeutics Initiates Rolling Submission of Biologics License Application to FDA for Lonvoguran Ziclumeran (lonvo-z) as a One-Time Treatment for Hereditary Angioedema
Intellia Therapeutics has initiated a rolling submission of a biologics license application (BLA) to the FDA for its CRISPR-based treatment, lonvo-z, for hereditary angioedema (HAE). The Phase 3 HAELO trial showed promising results, meeting all primary and secondary endpoints. If approved, lonvo-z could be the first in vivo CRISPR therapy, potentially transforming HAE treatment.
Read more →NTLAIntellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema, Marking a Global First for In Vivo Gene Editing
Intellia Therapeutics announced positive results from the Phase 3 HAELO trial of lonvoguran ziclumeran (lonvo-z) for hereditary angioedema. The trial met its primary and all key secondary endpoints, demonstrating a significant reduction in HAE attacks. A rolling biologics license application has been initiated with the FDA, aiming for a potential U.S. launch in early 2027.
Read more →About Intellia Therapeutics, Inc.
Headquarters40 ERIE STREET, CAMBRIDGE, MA, 02139
BIOPHARMAWATCH ELITE PLUS
Trade the next NTLA catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime